The Center for Biosimilars® recaps the top news for the week of October 15, 2018.
Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of October 15.
Number 5: During the American College of Rheumatology Annual Meeting, several research teams will present findings on nonmedical switching from reference products to biosimilars in the European Context.
Number 4: Ireland’s Medicines Management Program has opened a consultation related to its roadmap for prescribing best-value biologics in the Irish healthcare setting. The MMP will review the use of currently reimbursed anti-tumor necrosis factor therapies, which represent the highest-expenditure category for Ireland’s reimbursement plan.
Number 3: During a speech earlier this week, HHS Secretary Alex Azar proposed requiring drug companies to include the list price of a drug paid for by Medicare or Medicaid in direct-to-consumer television advertising.
Number 2: This week, UnitedHealthcare rolled out some of the changes it will be implementing in its Medicare Advantage plans beginning January 1, 2019, including listing 3 biosimilars as preferred treatments.
Number 1: Sandoz announced this week that its biosimilar adalimumab, Hyrimoz, became available in the United Kingdom, and Amgen announced that it will begin making its Amgevita available in multiple European markets. One day after the announcements from Sandoz and Amgen, Samsung Bioepis announced that it has launched its own biosimilar, Imraldi.
Finally, last week, our e-newsletter asked if Momenta’s change of direction signals trouble for the biosimilars market.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.